L M Weigel

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. ncbi Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus
    Linda M Weigel
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Science 302:1569-71. 2003
  2. ncbi A rapid antimicrobial susceptibility test for Bacillus anthracis
    Linda M Weigel
    National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G 08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 54:2793-800. 2010
  3. ncbi Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
    L M Weigel
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:3517-23. 2001
  4. ncbi DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis
    L M Weigel
    Division of Healthcare Quality Promotion, Anti infectives Section G 08, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 46:2582-7. 2002
  5. ncbi High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm
    Linda M Weigel
    NCID DHQP ELB MS G 08, Centers for Disease Control and Prevention, 1600 Clifton Road, N E, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 51:231-8. 2007
  6. ncbi gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
    L M Weigel
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 42:2661-7. 1998
  7. ncbi Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania
    Nancye C Clark
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G 08 Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 49:470-2. 2005
  8. ncbi Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 48:275-80. 2004
  9. ncbi Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure
    Cynthia J Whitener
    The Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Clin Infect Dis 38:1049-55. 2004
  10. ncbi Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia
    Ralf R Reinert
    Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital RWTH, Aachen, Germany
    Antimicrob Agents Chemother 52:2260-2. 2008

Detail Information

Publications11

  1. ncbi Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus
    Linda M Weigel
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Science 302:1569-71. 2003
    ..Genetic analyses suggest that the long-anticipated transfer of vancomycin resistance to a methicillin-resistant S. aureus occurred in vivo by interspecies transfer of Tn1546 from a co-isolate of Enterococcus faecalis...
  2. ncbi A rapid antimicrobial susceptibility test for Bacillus anthracis
    Linda M Weigel
    National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G 08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 54:2793-800. 2010
    ....
  3. ncbi Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
    L M Weigel
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:3517-23. 2001
    ..These data suggest that the heterogeneity of mutations will likely increase as pneumococci are exposed to novel fluoroquinolone structures, complicating the prediction of cross-resistance within this class of antimicrobial agents...
  4. ncbi DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis
    L M Weigel
    Division of Healthcare Quality Promotion, Anti infectives Section G 08, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 46:2582-7. 2002
    ..Unlike any other bacterial species analyzed to date, mutation of gyrB appears to be a frequent event in the acquisition of fluoroquinolone resistance among clinical isolates of P. mirabilis...
  5. ncbi High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm
    Linda M Weigel
    NCID DHQP ELB MS G 08, Centers for Disease Control and Prevention, 1600 Clifton Road, N E, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 51:231-8. 2007
    ..The potential for interspecies transfer of antimicrobial resistance genes, including resistance to vancomycin, may be enhanced by the microenvironment of a biofilm...
  6. ncbi gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
    L M Weigel
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 42:2661-7. 1998
    ..The type and position of amino acid alterations also differed among these six genera. High-level FQ-R frequently was associated with single gyrA mutations in all species of Enterobacteriaceae in this study except E. coli...
  7. ncbi Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania
    Nancye C Clark
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G 08 Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 49:470-2. 2005
    ..These differences in the Tn1546-like elements indicate that the first two VRSA isolates were the result of independent genetic events...
  8. ncbi Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 48:275-80. 2004
    ..The vanA sequence was identical to the vanA sequence present in Tn1546. A DNA probe for vanA hybridized to the 120-kb plasmid. This is the second VRSA isolate reported in the United States...
  9. ncbi Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure
    Cynthia J Whitener
    The Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania 17033, USA
    Clin Infect Dis 38:1049-55. 2004
    ..For clinical and public health reasons, it is essential that microbiology laboratories adequately test for vancomycin-resistance in S. aureus...
  10. ncbi Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia
    Ralf R Reinert
    Institute for Medical Microbiology, National Reference Center for Streptococci, University Hospital RWTH, Aachen, Germany
    Antimicrob Agents Chemother 52:2260-2. 2008
    ..7%], or both erm(B) and mef(E) (30.3%). Isolates with dual resistance genes [erm(B) and mef(E)] belonged to clonal complex CC81 or CC271...
  11. ncbi Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli
    Antonio Oliver
    Department of Microbiology, Ramon y Cajal Hospital, Madrid, Spain
    Antimicrob Agents Chemother 46:3829-36. 2002
    ..Such isolates should not be classified as containing ESBLs, nor should interpretations of ESCs or aztreonam susceptibility be changed to resistant on test reports for these isolates...